Mevo Health Review

Mevo Health: a four-doctor network selling both GLP-1s, in shots and tablets

Mevo Health is one of the few direct-pay telehealth shops that lets you pick not just your molecule but your route. It offers compounded semaglutide and compounded tirzepatide, each in both an injectable and an oral-tablet form. That four-way menu is genuinely uncommon — most cash-pay platforms hand you one drug as a weekly shot and call it a day. If the idea of swallowing a daily tablet instead of giving yourself an injection is what's been holding you back, Mevo is built for you. The catch, and we'll get to it, is that the company is thinner on the disclosures we use to judge safety than its pricing alone would suggest.

How the pricing actually works

Mevo runs a straight subscription. Semaglutide starts at $199 a month and tirzepatide a bit higher, and that figure is the medication itself — there's no insurance billing, no separate pharmacy run, you pay Mevo and the compounded drug ships to you. You can buy month-to-month or commit to a quarterly or six-month plan, which is where the real savings live; the longer blocks lower your effective monthly cost. For context, Mevo's entry rate sits a little above the category median of $170, so it's not the cheapest door on the block, but it's in the normal band for compounded GLP-1s.

One honest caveat on the price: every number Mevo publishes is an 'as low as' floor. There's no per-dose ladder and no statement that every dose costs the same, so what you actually pay as you titrate up isn't spelled out on the site. Treat the headline rate as a starting point and confirm your specific dose before you commit.

• Semaglutide — compounded, injection or oral tablet, from $199/month
• Tirzepatide — compounded, injection or oral tablet, priced a notch higher
• Plans — monthly, quarterly, or six-month; longer terms cut the per-month cost
• No insurance — direct-pay only; a separate online consult is required before any prescription

What you're actually getting in the box

Both drugs are compounded, not brand-name. That matters: the FDA does not review compounded medications for safety, effectiveness, or quality before they're dispensed, and Mevo — to its credit — prints that exact disclaimer on its own site rather than burying it. The drugs are made by what Mevo describes as '503A U.S. compounding pharmacies.' Plural is good in principle, but the company doesn't name them. Two pharmacy logos appear on the homepage without labels, so you can't independently check who is mixing your medication or look up their record. That's a real gap for a product you inject or ingest weekly.

The differentiator: named physicians and a LegitScript seal

Where Mevo separates itself from the faceless end of this market is its clinicians. Four board-certified physicians are named outright — Dr. David Wasef, who heads the provider network, plus Drs. Frank Suppa, Andrew Sakla, and Constantin Chikando, spanning internal, family, and emergency medicine. Putting real, verifiable names on the masthead is more transparency than a lot of competitors offer. Mevo also carries a LegitScript verification badge across multiple pages, which signals it has cleared that pharmacy-credentialing program.

Two things keep this from being a slam dunk. First, we couldn't independently confirm the LegitScript merchant ID through LegitScript's own lookup during our review — the badge is present, but the third-party check didn't complete, so we're trusting the seal rather than the registry. Second, Drs. Wasef and Suppa also appear on a couple of sibling telehealth brands. That's a common moonlighting pattern, not evidence of anything shady, and Mevo Health LLC is its own Delaware company — but if you're brand-loyal it's worth knowing the doctors aren't exclusive.

The disclosure gaps you should weigh

Our verification confidence on Mevo is medium, not high, and it's the missing paperwork that holds it there rather than any red flag. No state-availability list appears anywhere on the site, so you genuinely can't tell whether Mevo operates where you live until you start a consult. There's no titled Medical Director despite the named physicians, no SOC 2 certification claimed for data handling, and a small but telling footer typo — a 'HIPPA Policy' link — that doesn't inspire confidence in the back-office polish. None of these are dealbreakers on their own; together they're the difference between a provider you trust on sight and one you verify first.

Who should choose Mevo

• Anyone who specifically wants an oral-tablet GLP-1 instead of an injection — the both-routes menu is the standout reason to be here
• Shoppers who want both semaglutide and tirzepatide available from one provider so they can switch molecules without switching platforms
• People paying cash who value seeing named, board-certified doctors over an anonymous prescriber

Who should skip it

• Anyone who needs to confirm state coverage up front — Mevo doesn't publish where it operates
• Shoppers who want to vet the dispensing pharmacy by name before ordering compounded medication
• Patients hoping to use insurance or get brand-name Wegovy or Zepbound — Mevo is compounded, direct-pay only

The bottom line

Mevo Health earns its place for one concrete reason: the four-way drug-and-route menu is hard to find elsewhere, and it backs that up with real physician names, public floor pricing from $199, and the FDA compounding disclaimer printed in the open. It's a legitimate, transparent-enough direct-pay option. Just go in knowing the soft spots — unnamed pharmacies, no published state list, 'as low as' pricing rather than a full dose ladder — and confirm coverage and your actual dose cost before you pay. If you want to see how we weigh transparency, pricing, and oversight, our scoring methodology lays it out.

If you're weighing alternatives, RNK Health ($197/month) and Breeze Meds ($199/month) are among the closest options we track to Mevo Health.